Trinity Biotech: (NASD: TRIB)
$17.15
0.15 (0.88%)
Volume 11,821
Jun 18 04:00 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 17.02 - 17.39 |
| 52wk Low - High | 11.25 - 19.00 |
| Previous Close | 17.00 |
| Avg. Volume | 48,428 |
| Industry | MED PRODUCTS |
| Market Cap | 382.15 M |
| Div - Yield | 0.20 - 1.17 |
| Beta | 1.43 |
| P/E (F1) | 21.44 |
| Current Year Est. | 0.80 |
| Quarterly Earnings ESP |
NA |
Premium research
Zacks Rank
|
3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
184 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| P/E (F1) | 21.44 |
| PEG Ratio | 1.43 |
| Current Year Est. | 0.80 |
| Current Quarter Estimate | 0.20 |
| Most Accurate Estimate | NA |
| Earnings ESP |
NA |
| Next Earnings Report Date | 07-11-2013 |
| EPS Last Year | 0.78 |
| Expected Earnings Growth | 15.00% |
Company Description
Trinity Biotech plc, headquartered in Bray, the Republic of Ireland, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market worldwide. The company provides two haemostasis product lines, Biopool and Amax, comprising test kits and instrumentation used for the detection of blood disorders. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the blood, liver and intestine. The Company is also a provider of raw materials to the life sciences industry. It also engages in the provision of engineering, financial, and management services, as well as in trading business. Trinity Biotech sells its products through its sales force, as well as through a network of distributors and strategic partners.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | 0.20 | 0.21 | 0.80 | 0.96 |
| Number of Estimates | 3 | 3 | 3 | 3 |
| Low Estimate | 0.18 | 0.19 | 0.75 | 0.90 |
| High Estimate | 0.21 | 0.22 | 0.83 | NA |
| Year Ago EPS | 0.19 | 0.20 | 0.77 | 0.80 |
| EPS Growth | 3.51% | 3.33% | 3.90% | 20.00% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| TRINITY BIOTECH | TRIB | 17.15 | |
|
| HAEMONETICS CP | HAE | 42.71 | |
|
| ATRICURE INC | ATRC | 9.12 | |
|
| BAXANO SURGICAL | BAXS | 2.28 | |
|
| CARDICA INC | CRDC | 1.19 | |
|
| ESSILOR INTL SA | ESLOY | 55.99 | |
|
| INVIVO THERAPT | NVIV | 3.89 | |
|
| PURE BIOSCIENCE | PURE | 0.41 | |
|
| SHANDONG WEIGAO | SHWGF | 1.29 | |
|
| ABAXIS INC | ABAX | 46.89 | |
|
Sector:Medical>> Industry:MED PRODUCTS
COMPARE TICKER vs. Its Peers
Financials
| EPS TTM | 0.78 |
| Sales | 83 |
| Net Income | 17 |
| Price/Earnings | 21.99 |
| Price/Book | 2.10 |
| Price/Cash Flow | 18.14 |
| Price/Sales | 4.61 |
News
Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio - Benzinga
Apr 30, 2013
Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Operating Margin - Benzinga
Apr 18, 2013
Earnings Scheduled For March 5, 2013 - Benzinga
Mar 5, 2013
Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS Estimates For The Next Quarter - Benzinga
Feb 21, 2013
Stocks Hitting 52-Week Highs - Benzinga
Feb 15, 2013
These 2 "Goodwill Stocks" Could Help More Than 366 Million People - StreetAuthority
Jan 17, 2013
Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Profit Margin - Benzinga
Jan 8, 2013
Top 4 Stocks In The Diagnostic Substances Industry With The Highest Profit Margin - Benzinga
Dec 20, 2012
Broker Recommendations
| Current ABR | 1.67 |
| ABR (Last Week) | 2.00 |
| # of recs in ABR | 3 |
| Average Target Price | 20.50 |
| Industry Rank by ABR | 184 out of 265 |
| Rank in Industry | 9 out of 73 |
